Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on March 15, 2021, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to a newly-hired, non-executive employee. The inducement grants were approved by the Company’s compensation and talent strategy committee pursuant to a delegation by the Company’s board of directors and were made as a material inducement to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his employment compensation.
The inducement grants consisted of a non-statutory option to purchase 125,000 shares of the Company’s common stock, a grant of 60,000 restricted stock units for shares of the Company’s common stock and a grant of 10,000 restricted stock units for shares of the Company’s common stock.
The stock option has an exercise price of
Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company, please visit www.ivericbio.com.
ISEE-G
View source version on businesswire.com: https://www.businesswire.com/news/home/20210316005196/en/